Equity Overview
Price & Market Data
Price: $1.40
Daily Change: +$0.04 / 2.86%
Daily Range: $1.38 - $1.42
Market Cap: $51,163,920
Daily Volume: 1,571
Performance Metrics
1 Week: 7.51%
1 Month: -8.11%
3 Months: -20.47%
6 Months: -48.68%
1 Year: -4.90%
YTD: -16.05%
Company Details
Employees: 119
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Metagenomi Therapeutics, Inc. a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in EmeryVille, California.